EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial

Yasushi Ueki iD, Jonas D Häner, Sylvain Losdat, Giuseppe Gargiulo, Hiroki Shibutani, Sarah Bär, Tatsuhiko Otsuka, Raminta Kavaliauskaite, Vera R Mitter, Fabrice Temperli, David Spirk, Stefan Stortecky und 7 weitere

Thrombosis and Haemostasis · 2024-06 · 124 (06) · 517-527

DOI: 10.1055/a-2156-7872 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 11.09.2023. Verfasst von Yasushi Ueki und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Ticagrelor, Myocardial Infarction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: British Heart Foundation, Bern University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The effect of the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor alirocumab on platelet aggregation among patients with acute myocardial infarction (AMI) remains unknown. We aimed to explore the effect of alirocumab added to high-intensity statin therapy on P2Y12 reaction unit (PRU) among AMI patients receiving dual antiplatelet therapy (DAPT) with a potent P2Y12 inhibitor (ticagrelor or prasugrel). In addition, we assessed circulating platelet-derived noncoding RNAs (microRNAs and YRNAs).

Methods

This was a prespecified, powered, pharmacodynamic substudy of the PACMAN trial, a randomized, double-blind trial comparing biweekly alirocumab (150 mg) versus placebo in AMI patients undergoing percutaneous coronary intervention. Patients recruited at Bern University Hospital, receiving DAPT with a potent P2Y12 inhibitor, and adherent to the study drug (alirocumab or placebo) were analyzed for the current study. The primary endpoint was PRU at 4 weeks after study drug initiation as assessed by VerifyNow P2Y12 point-of-care assays.

Results

Among 139 randomized patients, the majority of patients received ticagrelor DAPT at 4 weeks (57 [86.4%] in the alirocumab group vs. 69 [94.5%] in the placebo group, p = 0.14). There were no significant differences in the primary endpoint PRU at 4 weeks between groups (12.5 [interquartile range, IQR: 27.0] vs. 19.0 [IQR: 30.0], p = 0.26). Consistent results were observed in 126 patients treated with ticagrelor (13.0 [IQR: 20.0] vs. 18.0 [IQR: 27.0], p = 0.28). Similarly, platelet-derived noncoding RNAs did not significantly differ between groups.

Conclusion

Among AMI patients receiving DAPT with a potent P2Y12 inhibitor, alirocumab had no significant effect on platelet reactivity as assessed by PRU and platelet-derived noncoding RNAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHydroxymethylglutaryl-CoA Reductase InhibitorsTicagrelorMyocardial InfarctionBlood PlateletsPlatelet Aggregation InhibitorsHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodDrug Therapy, CombinationPercutaneous Coronary InterventionPurinergic P2Y Receptor AntagonistsPlatelet AggregationTreatment OutcomePrasugrel HydrochloridePCSK9 InhibitorsDual Anti-Platelet TherapyProprotein Convertase 9

Substanzen

Antibodies, Monoclonal, HumanizedalirocumabHydroxymethylglutaryl-CoA Reductase InhibitorsTicagrelorPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsPrasugrel HydrochloridePCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Autor:innen und Institutionen

  • Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.
  • CTU Bern, University of Bern, Bern, Switzerland.
  • Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.
  • Institute of Hospital Pharmacy, Bern University Hospital, Bern, Switzerland.
  • Department of Pharmacology, Bern University, Bern and Sanofi, Switzerland.
  • Cardiocentro Ticino, Institute and Università della Svizzera Italiana (USI), Lugano, Switzerland.

ORCID-Profile: Yasushi Ueki

Förderung

  • British Heart Foundation
  • Bern University Hospital

Zitieren

APA

Ueki, Y., Häner, J. D., Losdat, S., Gargiulo, G., Shibutani, H., Bär, S., Otsuka, T., Kavaliauskaite, R., Mitter, V. R., Temperli, F., Spirk, D., Stortecky, S., Siontis, G. C. M., Valgimigli, M., Windecker, S., Gutmann, C., Koskinas, K. C., Mayr, M., & Räber, L. (2024). Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial. Thrombosis and Haemostasis, 124(06), 517-527. https://doi.org/10.1055/a-2156-7872

Vancouver

Ueki Y, Häner JD, Losdat S, Gargiulo G, Shibutani H, Bär S, et al. Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial. Thrombosis and Haemostasis. 2024;124(06):517-527. doi:10.1055/a-2156-7872

BibTeX
@article{Ueki2024,
  author = {Ueki, Yasushi and Häner, Jonas D and Losdat, Sylvain and Gargiulo, Giuseppe and Shibutani, Hiroki and Bär, Sarah and Otsuka, Tatsuhiko and Kavaliauskaite, Raminta and Mitter, Vera R and Temperli, Fabrice and Spirk, David and Stortecky, Stefan and Siontis, George C M and Valgimigli, Marco and Windecker, Stephan and Gutmann, Clemens and Koskinas, Konstantinos C and Mayr, Manuel and Räber, Lorenz},
  title = {Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {06},
  pages = {517--527},
  doi = {10.1055/a-2156-7872}
}
Kostenlos starten →